Barclays PLC Has $959,000 Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Barclays PLC grew its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 101.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 342,973 shares of the company’s stock after buying an additional 172,745 shares during the quarter. Barclays PLC owned approximately 0.16% of Allogene Therapeutics worth $959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in ALLO. Perceptive Advisors LLC acquired a new stake in shares of Allogene Therapeutics during the 2nd quarter valued at about $6,349,000. Lynx1 Capital Management LP acquired a new stake in shares of Allogene Therapeutics during the 2nd quarter valued at about $5,192,000. Renaissance Technologies LLC lifted its holdings in shares of Allogene Therapeutics by 340.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock valued at $4,073,000 after buying an additional 1,351,055 shares during the last quarter. Zacks Investment Management acquired a new stake in shares of Allogene Therapeutics during the 3rd quarter valued at about $1,446,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Allogene Therapeutics by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after buying an additional 507,021 shares during the last quarter. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $2.10 on Tuesday. The firm has a market cap of $440.31 million, a P/E ratio of -1.35 and a beta of 0.83. The business’s fifty day moving average is $2.41 and its two-hundred day moving average is $2.55. Allogene Therapeutics, Inc. has a 52 week low of $1.78 and a 52 week high of $5.78.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ALLO. William Blair reissued an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Piper Sandler cut their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Allogene Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).